Healthcare Industry News: bone graft
News Release - February 22, 2006
IsoTis OrthoBiologics Appoints Alan Donze as VP SalesLAUSANNE, Switzerland, IRVINE, California, February 22 (HSMN NewsFeed) -- IsoTis OrthoBiologics (SWX/Euronext: ISON) (TSX: ISO ) today announced it has appointed Alan Donze as Vice President Sales.
From 1991 until recently, Alan Donze was at Stryker Corporation, one of the world's largest orthopedic companies. From 1999 to 2004, Donze was Vice President and General Manager of Stryker Communications where he was instrumental in the development of the "Orthopedic Operating Room of the Future," using state of the art communication technology. In addition, Donze managed Stryker's Endoscopic Services program, which provided specialty outsourced technicians to the orthopedic surgical marketplace. Managed by Donze from start-up, both companies belong to Stryker's MedSurg Equipment division, the company's fastest growing business. Between 1991 and 1999, Alan held different sales and marketing positions of increasing responsibility at Stryker Endoscopy, including Director of Strategic Marketing, Southeast Regional Sales Manager and Endoscopy Sales Representative. He holds a BS from Louisiana State University.
Pieter Wolters, President and CEO of IsoTis OrthoBiologics said: "We are pleased to consistently attract top talent in the industry, and extend a warm welcome to Alan, who will lead our global sales effort. Throughout his career at Stryker Alan has shown leadership and entrepreneurial spirit in driving successful sales efforts in different surgical fields. Over the years he has built up a first rate network among surgeons and medical professionals at leading teaching institutions, which will bring great value to IsoTis."
Alan replaces former IsoTis Vice President of Sales Jim Abraham, who recently left the Company to operate a start-up opportunity in spine technology.
Wolters continued "We wish Jim Abraham all the best in his new endeavours. Jim was a highly valued member of our team and played an important role in focusing our sales effort and accelerating our 2005 growth."
IsoTis will publish its full year 2005 results on February 27 before markets open. At 3 p.m. CET/9 a.m. ET/6a.m. PT, the Company will hold an analyst meeting at SWX Convention Point in Zurich and a conference call to discuss these results.
IsoTis OrthoBiologics has a product portfolio with several innovative and proprietary natural and synthetic bone graft substitutes on the market and others in development, an established North American independent distribution network, and an expanding international presence.
Source: IsoTis OrthoBiologics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.